PROAlnylam Pharmaceuticals Inc
stock227.02
-5.66 (-2.43%)
Price as of 13 Oct, 12:30 · Rate limit reached. Please try again in a minute.
Good Money Guide Pro Score
Poor
Poor investment profile
Technical Analysis
Short-Term Outlook
Bearish
1 bull · 2 bear · 2 neutral
Medium-Term Outlook
Bearish
0 bull · 4 bear · 0 neutral
Price below 50-day MA
Price below 200-day MA
Price below 12-day EMA
Price below 26-day EMA
Neutral momentum zone
MACD below signal line
Oversold — potential reversal up
Price near middle band
Volatility measure — informational only
Volume Indicators
On Balance Volume (OBV)
Volume Accumulation Distribution (VAD)
Market Statistics
Day Change
-5.66
Market Cap
35710607000
Exchange
NASDAQ
Sector
HEALTHCARE
Fundamentals
Rate limit reached. Please try again in a minute.
Analyst Forecast
Rate limit reached. Please try again in a minute.
Fundamental Analysis
Unable to load fundamental data
Learn about Alnylam Pharmaceuticals Inc
What is Alnylam Pharmaceuticals Inc?
Alnylam Pharmaceuticals is a biopharmaceutical company that focuses on developing a new class of medicines based on RNA interference (RNAi). By utilizing this natural biological process, their treatments aim to silence the specific genes that cause rare and severe diseases, rather than just treating symptoms.
Is Alnylam Pharmaceuticals Inc a good investment?
The company is a leader in RNAi technology with several FDA-approved therapies, but it remains high-risk due to the costly nature of drug development and the volatility common in the biotechnology sector. Investors should weigh the company's innovation pipeline against the potential for clinical trial failures or regulatory hurdles. Please remember that this information is for educational purposes only and does not constitute financial advice.
How do you invest in Alnylam Pharmaceuticals Inc?
You can invest in Alnylam by purchasing shares directly through a standard brokerage account using its ticker symbol, ALNY. Alternatively, you can gain indirect exposure by investing in healthcare-focused exchange-traded funds (ETFs) or mutual funds that include Alnylam in their portfolio.
Educational content generated by AI — not financial advice.
Time & Sales
No trades yet.
News & Sentiment
Rate limit reached. Please try again in a minute.
Community Discussion
No posts yet for ALNY — be the first to start the discussion.
Point & Figure Analysis
Famous Investors Holding ALNY
Ken Griffin
177.6K sh · 0.0% of portfolio
$53.46M
NEW
Ray Dalio
99.6K sh · 0.1% of portfolio
$29.98M
NEW
Ken Griffin
81.6K sh · 0.0% of portfolio
$24.56M
NEW
Ken Griffin
42.5K sh · 0.0% of portfolio
$12.79M
NEW
Ken Griffin
13.4K sh · 0.0% of portfolio
$4.04M
NEW
Ken Fisher
6.3K sh · 0.0% of portfolio
$1.88M
NEW
Source: SEC Form 13F, reporting period 30 Jun 2026. 45-day lag applies.